Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label efgartigimod PH20 SC extension study in adult primary immune thrombocytopenia
2024-513147-90-00Phase 3Completed
- Sponsor
- argenx
- Start
- Apr 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 23
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa in immune thrombocytopenia (ITP), sponsored by argenx. Primary endpoints: Incidence, frequency, and severity of adverse events and Safety assessments. Started Apr 2022; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2024-513147-90-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513147-90-00.